Skip to main content

Asuragen Licenses Roche's qRT-PCR IP for Drug Trials Work

NEW YORK (GenomeWeb News) — Asuragen Pharmacogenomic Services today said it has licensed real-time quantitative PCR technology from Roche Molecular Systems that will enable it to perform clinical gene-expression profiling and DNA analysis.
 
Asuragen said the IP, together with its microRNA and mRNA profiling services, can be used to test predictive biomarker signatures, efficacy markers, and assess patient stratification during clinical drug trials.
 
Financial terms of the agreement were not released.

The Scan

Response Too Slow, Cautious

A new report criticizes the global response to the threat of the COVID-19 pandemic, Nature News reports.

Pushed a Bit Later

Novavax has pushed back its timeline for filing for authorization for its SARS-CoV-2 vaccine, according to Bloomberg.

AMA Announces Anti-Racism Effort

The Associated Press reports that the American Medical Association has released a plan to address systemic racism in healthcare.

Nucleic Acids Research Papers on miRMaster 2.0, MutationTaster2021, LipidSuite

In Nucleic Acids Research this week: tool to examine small non-coding RNAs, approach to predict ramifications of DNA variants, and more.